Read the latest Nanopinion guest column from Dr. Anita Jemec Kokalj and Dr. Dana Kühnel about defining the criteria to evaluate which properties of nanoplastics should be reported in future studies to decrease uncertainties in the risk assessment of nanoplastics.
ECHA has published an update to the Appendix for nanoforms applicable to the Guidance on Registration and Substance Identification (v.2.0).
The main changes include additional guidance on the joint submission of data, clarifications regarding the need for one dataset per nanoform/set of nanoforms and information on the registration of sets of nanoforms versus single nanoforms.
Read the latest Nanopinion guest column from Dr. Alberto Bianco, Dr. Maurizio Prato and Dr. Kostas Kostarelos, from Graphene Flagship, about graphene and why it’s not the same as carbon nanotubes.
Read the latest Nanopinion guest column from Dr. Eugenia Valsami-Jones about ACEnano, a Horizon2020 project which has recently completed its 4.5-year course. The main goal of the project was to strengthen clarity into nanomaterial risk assessment by a tiered approach to nanomaterials physiochemical characterisation.
Are substances in nanoforms more dangerous than they are in their normal size? Some are and some are not. Just like any other chemical substance, nanomaterials have to be assessed separately.
Nanomaterials are not only used in consumer products, but also in new and innovative medical treatments. Research has shown that nanoparticles can be used to damage and even destroy cancer cells from within.
Nano 360°
Visit our interactive apartment and car shop to learn how nanomaterials are used and how to stay safe.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.